Thirdly, outcome measures and length of follow-up for outcome assessment were not assessed in this analysis.
The freshwater reptile and fish assessments used in this analysis were selected and assessed for the sampled approach to red-listing, and therefore correspond to a representative random sample of species from these classes rather than assessments for all species in the group (Baillie et al., 2008; Collen & Baillie, 2010).
Such assessments conducted in this analysis include a dynamic climate but assume constant aboveground biomass stocks, and a stand origin and phylogeny (e.g., conifer- or hardwood-dominated forest type).
Therefore, the analysis was conducted excluding ratings of "not observed" such that 134 of the 822 assessments were not considered reliable for inclusion leaving 688 assessments in the analysis.
Assessment tools in this analysis comprised the measures of cognition, function, behavior (neuropsychiatric symptoms), and global clinical status utilized in the individual trials.
The variables from the MDS assessment used in this analysis were demographic variables (age, gender, year of admittance, place admitted from, and month of death) and scores from scales and indices developed especially for the MDS which can be used to monitor changes over time.
Nine trials, involving 504 patients, assessed as lower risk of bias (domain-based assessment) were included in this analysis.
For death at final follow-up in trials assessed as lower risk of bias, 14 trials involving 918 patients and assessed as lower risk of bias (domain-based assessment) were included in this analysis.
For poor outcome at final follow-up in trials assessed as lower risk of bias, 16 trials, involving 964 patients, and assessed as lower risk of bias (domain-based assessment) were included in this analysis.
However, only the first completed assessment was used in this analysis.
